1. Home
  2. TRT vs VTVT Comparison

TRT vs VTVT Comparison

Compare TRT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trio-Tech International

TRT

Trio-Tech International

HOLD

Current Price

$4.92

Market Cap

109.1M

Sector

Technology

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

N/A

Current Price

$26.54

Market Cap

129.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRT
VTVT
Founded
1958
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.1M
129.7M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
TRT
VTVT
Price
$4.92
$26.54
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $56.00
AVG Volume (30 Days)
★ 423.6K
28.6K
Earning Date
09-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 100.00
N/A
EPS
N/A
N/A
Revenue
★ $32,462,000.00
N/A
Revenue This Year
$26.89
N/A
Revenue Next Year
$25.30
N/A
P/E Ratio
$365.50
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.63
$19.80
52 Week High
$21.38
$44.00

Technical Indicators

Market Signals
Indicator
TRT
VTVT
Relative Strength Index (RSI) 22.48 31.34
Support Level $4.42 N/A
Resistance Level $6.54 $34.65
Average True Range (ATR) 0.32 1.35
MACD -0.05 -0.35
Stochastic Oscillator 4.93 0.18

Price Performance

Historical Comparison
TRT
VTVT

About TRT Trio-Tech International

Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: